{"provider_name":"Hatena Blog","blog_url":"https://uneyama.hatenadiary.jp/","blog_title":"\u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b","url":"https://uneyama.hatenadiary.jp/entry/20160308/p8","published":"2016-03-08 00:00:07","type":"rich","provider_url":"https://hatena.blog","author_name":"uneyama","title":"\u5206\u5b50\u6a19\u7684\u7642\u6cd5\u306e\u305f\u3081\u306e\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u691c\u67fb\u306e\u6709\u52b9\u6027\u3068\u5229\u7528\u53ef\u80fd\u6027\u6539\u5584\u306e\u305f\u3081\u306b\u306f\u3088\u308a\u826f\u3044\u6839\u62e0\u3068\u76e3\u8996\u304c\u5fc5\u8981","author_url":"https://blog.hatena.ne.jp/uneyama/","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Funeyama.hatenadiary.jp%2Fentry%2F20160308%2Fp8\" title=\"\u5206\u5b50\u6a19\u7684\u7642\u6cd5\u306e\u305f\u3081\u306e\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u691c\u67fb\u306e\u6709\u52b9\u6027\u3068\u5229\u7528\u53ef\u80fd\u6027\u6539\u5584\u306e\u305f\u3081\u306b\u306f\u3088\u308a\u826f\u3044\u6839\u62e0\u3068\u76e3\u8996\u304c\u5fc5\u8981 - \u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","height":"190","image_url":null,"version":"1.0","categories":["NAS"],"width":"100%","description":"Better Evidence, Oversight Needed to Improve Effectiveness and Availability of Biomarker Tests for Molecularly Targeted Therapies, Says New Report March 4, 2016 http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=21860"}